The Pancreatic Adenocarcinoma Gene Environment Risk Study -A Prospective Cohort Study of Patients at Risk or Having Pancreatic Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pancreatic Cancer
- Sponsor
- University of Pittsburgh
- Enrollment
- 10000
- Locations
- 1
- Primary Endpoint
- The data will be used in cohort association studies. Endpoints will depend on the number of patients in the study and the number of markers that are being evaluated.
- Status
- Recruiting
- Last Updated
- 5 months ago
Overview
Brief Summary
After informed consent, participants will be asked to complete a medical/family history questionnaire and provide a blood sample. Some participants may also be asked to provide a urine sample. Individuals undergoing procedures that require collection of biological samples for clinical purposes may have these samples saved for research purposes. Participants will also be asked for their permission for study investigators to access medical records and/or recontact them for updates to their medical and family histories. Data and biospecimens will be stored for potential future research projects.
Investigators
Randall Brand
M.D.
University of Pittsburgh
Eligibility Criteria
Inclusion Criteria
- •Histologically confirmed or CT confirmed diagnosis of pancreatic adenocarcinoma
- •Subjects with abnormal imaging study (CT, MRI, MRCP, EUS)
- •Control subjects with a clinical diagnosis of a pancreas, liver, or intestinal condition
- •Control subject with acute pancreatitis
- •Control subject with chronic pancreatitis
- •Control subject with biliary obstruction
- •Control subject with pancreatic cyst
- •Member of a high risk family (≥ 1 close relative with pancreatic cancer)
- •Healthy control (without any of the above conditions)
Exclusion Criteria
- •Under the age of 18 years
- •Unable to give informed consent
- •Inability to travel to Pittsburgh for in-person enrollment
Outcomes
Primary Outcomes
The data will be used in cohort association studies. Endpoints will depend on the number of patients in the study and the number of markers that are being evaluated.
Time Frame: 10 years